12 studies were found.

1.		Recruiting	Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Condition: recurrent mantle cell lymphoma
2.		Recruiting	EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-segment Elevation Acute Coronary Syndrome Condition: Myocardial Ischemia
3.		Recruiting	MLN2704 in Subjects with Metastatic Androgen-Independent Prostate Cancer Condition: Prostatic Neoplasms
4.		Recruiting	Phase 1 Single Ascending Dose Trial of MLN2704 in Subjects with Metastatic Androgen Independent Prostate Cancer Condition: Prostate Cancer
5.		Recruiting	Phase 2 Study of VELCADE in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma
6.		Recruiting	A Phase 2 Study of VELCADE® (bortezomib) with Rituximab in Subjects with Relapsed or Refractory Indolent B-Cell Lymphoma Conditions: B-Cell Lymphoma; Follicular Lymphoma; Marginal Lymphoma
7.		Recruiting	PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
8.		Recruiting	Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma Condition: Multiple Myeloma
9.		Recruiting	Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients with Acute Myelogenous Leukemia (AML) Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
10.		Recruiting	Study of Combination PS-341 and Thalidomide in Multiple Myeloma Condition: Multiple Myeloma
11.		Recruiting	A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 Condition: Multiple Myeloma
12.		Recruiting	UARK 2003-33, Total Therapy III Condition: Multiple Myeloma